NAPSR News: Novo Nordisk's Tresiba Makes a Solid Start

The roll-out of Novo Nordisk's ultra-long-acting insulin Tresiba is off to an encouraging start, picking up sales of around $15 million USD in the first quarter of the year.
By:
 
WASHINGTON - May 5, 2014 - PRLog -- Novo Nordisk has a lot riding on Tresiba (insulin degludec), which has been pitched as a key growth product for the company in the coming years. The company suffered a setback in the US last year after an FDA request for cardiovascular outcomes data delayed approval, so a strong showing in other markets is critical.

In its first-quarter results statement, Novo Nordisk notes that Tresiba is doing well in countries where it has secured reimbursement at a similar level to market leading basal insulin - Sanofi's $8 billion blockbuster Lantus (insulin glargine).

Tresiba has captured between 10-17% of the basal insulin market in these countries, measured in monthly value market share, according to the company, although it notes uptake has been "modest" in markets with restricted market access compared to Lantus.

So far, Tresiba is available in 12 countries, including Germany and Japan, with 20 more launches expected before the end of the year. Novo is in the midst of building a $100 million facility in Denmark to handle the anticipated growth in Tresiba demand.

Tresiba could get a boost from the results of the DEVOTE trial, a cardiovascular outcomes study involving 7,500 diabetes patients which is due to generate interim data in mid-2015, around a year earlier than expected.

Novo Nordisk chief executive Lars Rebien Sørensen said rapid recruitment into DEVOTE "enables us to shorten the timeline for the interim analysis and a potential US launch".

Overall, the company's sales grew 2% in the first quarter to reach $3.78 billion USD, with 4% growth in modern insulins offsetting a 9% drop in sales of its older human insulin range.

GLP-1 agonist Victoza (liraglutide) did fairly well in the quarter, adding 9% to reach $543 million USD, although its growth was pegged back by a partial loss of reimbursement with a large pharmacy benefit manager in the US.

NOW IS THE TIME TO ENTER INTO THIS WONDERFUL FIELD!

With such industry leaders posting gains in profitability, they will need both certified and qualified individuals to sell their product. When industry leaders look for new candidates for entry level positions, they look toward individuals that are industry trained. Reason being that they are looking for people that have the background to sell their product both proficiently and efficiantly.

CANDIDATES WHO WANT TO BREAK INTO PHARMACEUTICAL SALES!

Upon successful completion of the training each student will receive the Certification Mark of the CNPR®. The CNPR® represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Pharmaceutical sales candidates who have this training will differentiate themselves from other individuals looking for open positions. CNPR® graduates should immediately utilize the NAPSRx® Career Center to apply for pharmaceutical sales positions.

The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals. The CNPR examination is dedicated to increasing the professional level of NAPSR members and to developing meaningful and ethical standards fully accepted by both its members and members of the pharmaceutical community.

Individuals that are interested in becoming a Certified National Pharmaceutical Representative(CNPR) can contact the National Association of Pharmaceutical Sales Representatives(NAPSRx) for more information.

Contact
NAPSRx
***@napsronline.org
800-284-1060
End
Source: » Follow
Email:***@napsronline.org Email Verified
Tags:Napsrx, Cnpr, Pharmaceutical Sales, Certification, Training
Industry:Biotech, Medical
Location:Washington - District of Columbia - United States
Subject:Earnings
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
NAPSRx PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share